"United Kingdom Pharmaceuticals & Healthcare Report Q4 2014" now available at Fast Market Research

The UK has traditionally had high state healthcare expenditure, with patients enjoying free access to doctors and specialists, and easy access to medicines. However, the government currently accounts for more than three-quarters of healthcare spending, and the expanding, ageing population will continue to boost demand for healthcare, pushing the government to focus on cost containment.

Headline Expenditure Projections

Pharmaceuticals: GBP24,53bn (USD38.01bn) in 2013 to GBP24.67bn (USD40.95bn) in 2014; +0.59% in local currency terms and +7.7% in US dollar terms.

Healthcare: GBP148.54bn (USD230.23bn) in 2013 to GBP152.05bn (USD252.39bn) in 2014; +2.4% in local currency terms and +9.6% in US dollar terms.

Full Report Details at
- http://www.fastmr.com/prod/900695_united_kingdom_pharmaceuticals_healthcare_report.aspx?afid=301

Risk/Reward Rating

The UK is ranked fourth out of the 15 markets profiled in the Western Europe region. While its developed healthcare system and the predicable operating environment support its attractiveness from the point of view of research-based manufacturers, the downward pressure on prices and a general climate of cost-containment in relation to pharmaceutical spending will continue to weigh down on its longer-term market opportunities. Nevertheless, we are still broadly optimistic that the UK's pharmaceutical market will remain one of the most attractive globally.

Key Trends And Developments

Highlighting revenue pressures for innovative drugmakers operating in the UK, on June 30 2014, the Association of the British Pharmaceutical Industry (ABPI) and the UK's Department of Health announced the payment of a rebate of GBP74mn (USD126mn) by industry to underwrite the growth in the branded medicines bill under the 2014 Pharmaceutical Price Regulation Scheme (PPRS). The payment accounts for the first three months of 2014.

In August 2014, the UK's cost-effectiveness watchdog, the National Institute for Health and Care Excellence (NICE), granted provisional approval for Gilead Sciences' Sovaldi (sofosbuvir), paving the way for the drug's procurement by...

The United Kingdom Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's United Kingdom Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the British pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for United Kingdom to test other views - a key input for successful budgeting and strategic business planning in the British pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- United States Pharmaceuticals & Healthcare Report Q4 2014
- United Arab Emirates Pharmaceuticals & Healthcare Report Q4 2014
- Jordan Pharmaceuticals & Healthcare Report Q4 2014
- South Korea Pharmaceuticals & Healthcare Report Q4 2014
- Sweden Pharmaceuticals & Healthcare Report Q4 2014